NEW YORK (GenomeWeb News) – Becton Dickinson has completed its $275 million acquisition of molecular diagnostics firm HandyLab, the firm said today.
HandyLab sells the Jaguar molecular diagnostics system, which incorporates clinical sample preparation, nucleic acid extraction, microfluidic real-time PCR amplification and detection. The Ann Arbor, Mich.-based firm launched the system in November 2008.
BD said that it plans to place its BD GeneOhm assays for methicillin-resistant Staphylococcus aureus, Clostridium difficile, and vancomycin-resistant Enterococcus on the HandyLab platform and market them as the new BD Max system. It said that the BD Max system is an evolution of the current Jaguar system.
The acquisition follows an alliance between the firms begun earlier this year aimed at placing the GeneOhm tests on the Jaguar system.
BD announced the deal to acquire HandyLab last month, but it did not provide the purchase price at that time.